Jing Zhou, MD, PhD

Jing Zhou, MD, PhD, is the chief scientific officer at IsoPlexis. She has led multiple studies with various biopharma and trial center leaders, particularly in the immuno-oncology space, to develop single-cell polyfunctional metrics that can distinguish and predict patient response to CAR-T and antibody-based cancer immunotherapies. Prior to IsoPlexis, she was an immunologist at the Yale School of Medicine with expertise in defining phenotype and functionality of immune cells in diseased and healthy settings, with 30+ scientific publications in leading journals. Jing earned her medical degree in clinical medicine from Bengbu Medical College, MS and PhD in immunology from Shanghai Jiao Tong University, and has been the principal investigator of NIH, AHA, and Yale University grants.